1. Home
  2. Labeler Index
  3. Dispensing Solutions, Inc.
  4. 68258-6095
  5. Product Images: Valsartan And Hydrochlorothiazide

Product Images Valsartan And Hydrochlorothiazide

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 8 images provide visual information about the product associated with Valsartan And Hydrochlorothiazide NDC 68258-6095 by Dispensing Solutions, Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

NDC 68258-6095-XX - NDC 68258 6095 XX NOVARTIS

NDC 68258-6095-XX - NDC 68258 6095 XX NOVARTIS

This text provides information on bulk source data for a medicine produced by Novartis Pharmaceuticals Corp. The medicine is a dark red oval tablet with the imprint CG/HHH and is dispensed in a tight/light resistant container. It contains 160 mg of Valsartan USP and 12.5 mg of Hydrochlorothiazide USP. The medicine may cause drowsiness, dizziness or headache and should be taken orally once daily as directed by a doctor. The text also provides the NDC, product ID, pedigree number, MFR.LOT number, and warnings regarding pregnancy and children's reach. The summary ends with information on packaging by Dispensing Solutions of Santa Ana, CA.*

NDC 68258-6096-XX - NDC 68258 6096 XX NOVARTIS

NDC 68258-6096-XX - NDC 68258 6096 XX NOVARTIS

This is a bulk source data sheet for a pharmaceutical product that contains hydrochlorothiazide and valsartan, manufactured by Novartis Pharmaceuticals Corp. The product is an oval-shaped tablet that is brown in color and has a slightly convex shape. It is labeled with the product ID and the NDC, which is 00781-5950-10. The drug is packed in a tight/light resistant container and should be taken orally once daily as directed by a doctor. The lot number is XXXXXX, and the pedigree number is 046-834619. The text includes warnings such as possible side effects and the risk of fetal harm if taken during pregnancy. The product is packaged in Santa Ana, CA, by Dispensing Solution.*

Figure 1: Probability of Achieving Systolic Blood Pressure <140 mmHg at Week 8 - valsartan hct 1

Figure 1: Probability of Achieving Systolic Blood Pressure <140 mmHg at Week 8 - valsartan hct 1

Figure 2: Probability of Achieving Diastolic Blood Pressure <90 mmHg at Week 8 - valsartan hct 2

Figure 2: Probability of Achieving Diastolic Blood Pressure <90 mmHg at Week 8 - valsartan hct 2

Figure 3: Probability of Achieving Systolic Blood Pressure <130 mmHg at Week 8 - valsartan hct 3

Figure 3: Probability of Achieving Systolic Blood Pressure <130 mmHg at Week 8 - valsartan hct 3

Figure 4: Probability of Achieving Diastolic Blood Pressure <80 mmHg at Week 8 - valsartan hct 4

Figure 4: Probability of Achieving Diastolic Blood Pressure <80 mmHg at Week 8 - valsartan hct 4

valsartan chemical structure - valsartan hct 5

valsartan chemical structure - valsartan hct 5

Hydrochlorothiazide chemical structure - valsartan hct 6

Hydrochlorothiazide chemical structure - valsartan hct 6

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.